153 related articles for article (PubMed ID: 34313746)
1. Evaluation of Frequency of Administration of Intravenous Bisphosphonate and Recurrent Skeletal-Related Events in Patients With Multiple Myeloma.
Zhou J; Sweiss K; Han J; Ko NY; Patel PR; Chiu BC; Calip GS
JAMA Netw Open; 2021 Jul; 4(7):e2118410. PubMed ID: 34313746
[TBL] [Abstract][Full Text] [Related]
2. Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer.
Crawford BS; McNulty RM; Kraut EH; Turowski RC
Cancer Invest; 2009 Dec; 27(10):984-8. PubMed ID: 19909013
[TBL] [Abstract][Full Text] [Related]
3. Use of bisphosphonates in metastatic breast cancer: single institution review at the Dr. H. Bliss Murphy Cancer Centre.
Murphy L; McCarthy J; McCrate F; Laing K; Powell E; Seal M; Edwards S
Support Care Cancer; 2013 Jun; 21(6):1557-60. PubMed ID: 23334521
[TBL] [Abstract][Full Text] [Related]
4. Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma.
Menssen HD; Sakalová A; Fontana A; Herrmann Z; Boewer C; Facon T; Lichinitser MR; Singer CR; Euller-Ziegler L; Wetterwald M; Fiere D; Hrubisko M; Thiel E; Delmas PD
J Clin Oncol; 2002 May; 20(9):2353-9. PubMed ID: 11981007
[TBL] [Abstract][Full Text] [Related]
5. Prolonged administration of bisphosphonates is well-tolerated and effective for skeletal-related events in Chinese breast cancer patients with bone metastasis.
Ding X; Fan Y; Ma F; Li Q; Wang J; Zhang P; Yuan P; Xu B
Breast; 2012 Aug; 21(4):544-9. PubMed ID: 22627092
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group.
Berenson JR; Lichtenstein A; Porter L; Dimopoulos MA; Bordoni R; George S; Lipton A; Keller A; Ballester O; Kovacs MJ; Blacklock HA; Bell R; Simeone J; Reitsma DJ; Heffernan M; Seaman J; Knight RD
N Engl J Med; 1996 Feb; 334(8):488-93. PubMed ID: 8559201
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the clinical benefit of long-term (beyond 2 years) treatment of skeletal-related events in advanced cancers with zoledronic acid.
Henk H; Teitelbaum A; Kaura S
Curr Med Res Opin; 2012 Jul; 28(7):1119-27. PubMed ID: 22536885
[TBL] [Abstract][Full Text] [Related]
8. A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer.
Zaghloul MS; Boutrus R; El-Hossieny H; Kader YA; El-Attar I; Nazmy M
Int J Clin Oncol; 2010 Aug; 15(4):382-9. PubMed ID: 20354750
[TBL] [Abstract][Full Text] [Related]
9. International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease.
Terpos E; Morgan G; Dimopoulos MA; Drake MT; Lentzsch S; Raje N; Sezer O; García-Sanz R; Shimizu K; Turesson I; Reiman T; Jurczyszyn A; Merlini G; Spencer A; Leleu X; Cavo M; Munshi N; Rajkumar SV; Durie BG; Roodman GD
J Clin Oncol; 2013 Jun; 31(18):2347-57. PubMed ID: 23690408
[TBL] [Abstract][Full Text] [Related]
10. Intravenous pamidronate for myeloma bone disease: can the dose be lowered?
Terpos E; Dimopoulos MA
Lancet Oncol; 2010 Oct; 11(10):913-4. PubMed ID: 20863760
[No Abstract] [Full Text] [Related]
11. Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial.
Gimsing P; Carlson K; Turesson I; Fayers P; Waage A; Vangsted A; Mylin A; Gluud C; Juliusson G; Gregersen H; Hjorth-Hansen H; Nesthus I; Dahl IM; Westin J; Nielsen JL; Knudsen LM; Ahlberg L; Hjorth M; Abildgaard N; Andersen NF; Linder O; Wisløff F
Lancet Oncol; 2010 Oct; 11(10):973-82. PubMed ID: 20863761
[TBL] [Abstract][Full Text] [Related]
12. [Multiple myeloma].
Abe M
Nihon Rinsho; 2009 May; 67(5):991-5. PubMed ID: 19432122
[TBL] [Abstract][Full Text] [Related]
13. Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease.
Terpos E; Dimopoulos MA; Berenson J
Crit Rev Oncol Hematol; 2011 Feb; 77 Suppl 1():S13-23. PubMed ID: 21353176
[TBL] [Abstract][Full Text] [Related]
14. A once-yearly IV bisphosphonate for osteoporosis.
Med Lett Drugs Ther; 2007 Nov; 49(1273):89-90. PubMed ID: 17975523
[No Abstract] [Full Text] [Related]
15. Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Results of the Z-MARK Study.
Raje N; Vescio R; Montgomery CW; Badros A; Munshi N; Orlowski R; Hadala JT; Warsi G; Argonza-Aviles E; Ericson SG; Anderson KC
Clin Cancer Res; 2016 Mar; 22(6):1378-84. PubMed ID: 26644410
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic options in the management of myeloma bone disease.
Berenson JR
Semin Oncol; 2010 Jun; 37 Suppl 1():S20-9. PubMed ID: 20682368
[TBL] [Abstract][Full Text] [Related]
17. A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events.
Iyer SP; Beck JT; Stewart AK; Shah J; Kelly KR; Isaacs R; Bilic S; Sen S; Munshi NC
Br J Haematol; 2014 Nov; 167(3):366-75. PubMed ID: 25139740
[TBL] [Abstract][Full Text] [Related]
18. Osteoporosis. Letter to the editor.
Namazi H
Curr Med Res Opin; 2012 Nov; 28(11):1755. PubMed ID: 22978776
[No Abstract] [Full Text] [Related]
19. Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group.
Brincker H; Westin J; Abildgaard N; Gimsing P; Turesson I; Hedenus M; Ford J; Kandra A
Br J Haematol; 1998 May; 101(2):280-6. PubMed ID: 9609523
[TBL] [Abstract][Full Text] [Related]
20. Supportive therapy in multiple myeloma.
Ludwig H; Zojer N
Recent Results Cancer Res; 2011; 183():307-33. PubMed ID: 21509692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
